Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences (Nasdaq: PCRX) granted inducement equity awards on March 3, 2026 to three new employees under its Amended and Restated 2014 Inducement Plan as permitted by Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Summary
Pacira BioSciences (Nasdaq: PCRX) granted inducement equity awards on March 3, 2026 to three new employees under its Amended and Restated 2014 Inducement Plan as permitted by Nasdaq Listing Rule 5635(c)(4).
One hire received options for 2,400 shares (10-year term, $22.10 exercise price, four-year vesting). Three hires received 5,500 RSUs vesting annually over four years beginning March 1, 2027.
Positive
- None.
Negative
- None.
Details
News Market Reaction – PCRX
On Mar 6, the day this news came out, PCRX closed 3.76% below the previous close.
Data tracked by StockTitan Argus for the Mar 6 session.
Key Figures
- Inducement stock options
- 2,400 shares
- Granted to one new employee under 2014 Inducement Plan
- Inducement RSUs
- 5,500 shares
- Aggregate RSUs granted to three new employees
- Option term
- 10 years
- Term of inducement stock options granted March 3, 2026
- Vesting period
- 4 years
- Equity awards vest over four-year schedules
- Initial cliff vesting
- 25 percent
- Options vest 25% on first anniversary of employment start date
- Subsequent vesting period
- 36 months
- Remaining option shares vest in equal quarterly installments
- Exercise price
- $22.10 per share
- Closing price on Nasdaq Global Select Market on grant date
- RSU vesting schedule
- 4 annual installments
- RSUs vest annually starting March 1, 2027
Historical Context
-
Announcement of a Barclays healthcare conference fireside chat and webcast access.
-
IGOR real-world data showing benefits for EXPAREL and iovera° in knee pain.
-
Q4 and full-year 2025 results with revenue growth and positive net income.
-
Scheduling announcement for release of 2025 financial results and conference call.
-
NOPAIN Act survey highlighting increased non-opioid use and reduced opioid prescribing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
inducement plan financial
stock options financial
restricted stock units financial
vesting schedule financial
exercise price financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on March 3, 2026 to three new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.
One employee received stock options to purchase an aggregate of 2,400 shares of Pacira common stock and three employees received restricted stock units for an aggregate of 5,500 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient’s first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of
Vesting of the equity awards is subject to the employee’s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.

Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com Media Contact: Sara Marino, (973) 370-5430 sara.marino@pacira.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.